AR057357A1 - Heterociclos nitrogenados como inhibidores de heteroaril 11-beta hidroxiesteroide deshidrogenasa tipo 1. composiciones farmaceuticas - Google Patents
Heterociclos nitrogenados como inhibidores de heteroaril 11-beta hidroxiesteroide deshidrogenasa tipo 1. composiciones farmaceuticasInfo
- Publication number
- AR057357A1 AR057357A1 ARP060102405A ARP060102405A AR057357A1 AR 057357 A1 AR057357 A1 AR 057357A1 AR P060102405 A ARP060102405 A AR P060102405A AR P060102405 A ARP060102405 A AR P060102405A AR 057357 A1 AR057357 A1 AR 057357A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroaryl
- heterocyclyl
- aryl
- alkyl
- optionally substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 21
- 125000000623 heterocyclic group Chemical group 0.000 abstract 19
- 125000003118 aryl group Chemical group 0.000 abstract 18
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical class 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 11
- -1 heteroatylamino Chemical group 0.000 abstract 11
- 125000003545 alkoxy group Chemical group 0.000 abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000001769 aryl amino group Chemical group 0.000 abstract 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 2
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- BGCPLWWYPZAURQ-UHFFFAOYSA-N 5-[[5-chloro-2-(2,2,6,6-tetramethylmorpholin-4-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one Chemical compound ClC=1C(=NC(=NC=1)N1CC(OC(C1)(C)C)(C)C)NC1=CC2=C(N(C(N2CCC(C)(C)O)=O)C)C=C1 BGCPLWWYPZAURQ-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101001061911 Homo sapiens Ras-related protein Rab-40A Proteins 0.000 abstract 1
- 102100029553 Ras-related protein Rab-40A Human genes 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000005082 alkoxyalkenyl group Chemical group 0.000 abstract 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 abstract 1
- 125000005418 aryl aryl group Chemical group 0.000 abstract 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000005325 aryloxy aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68899305P | 2005-06-09 | 2005-06-09 | |
| US11/448,946 US7572807B2 (en) | 2005-06-09 | 2006-06-07 | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057357A1 true AR057357A1 (es) | 2007-11-28 |
Family
ID=37524860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102405A AR057357A1 (es) | 2005-06-09 | 2006-06-08 | Heterociclos nitrogenados como inhibidores de heteroaril 11-beta hidroxiesteroide deshidrogenasa tipo 1. composiciones farmaceuticas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7572807B2 (OSRAM) |
| EP (1) | EP1912986B1 (OSRAM) |
| JP (1) | JP5124450B2 (OSRAM) |
| KR (1) | KR20080018942A (OSRAM) |
| AR (1) | AR057357A1 (OSRAM) |
| AU (1) | AU2006258077B2 (OSRAM) |
| ES (1) | ES2392656T3 (OSRAM) |
| MX (1) | MX2007015283A (OSRAM) |
| NO (1) | NO20076054L (OSRAM) |
| PE (1) | PE20070002A1 (OSRAM) |
| TW (1) | TW200716116A (OSRAM) |
| WO (1) | WO2006135667A1 (OSRAM) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1966214B9 (en) | 2005-12-21 | 2017-09-13 | Janssen Pharmaceutica N.V. | Triazolopyridazines as tyrosine kinase modulators |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| JP5244091B2 (ja) * | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8236841B2 (en) * | 2006-09-13 | 2012-08-07 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocycle derivative |
| CA2665195C (en) * | 2006-10-11 | 2011-08-09 | Amgen Inc. | Imidazo- and triazolo-pyridine compounds and methods of use thereof |
| KR20090094336A (ko) | 2006-11-27 | 2009-09-04 | 하. 룬트벡 아크티에 셀스카브 | 헤테로아릴 아미드 유도체 |
| AU2007337886C1 (en) | 2006-12-22 | 2014-10-16 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| CN101679409B (zh) | 2006-12-22 | 2014-11-26 | Astex治疗学有限公司 | 双环杂环衍生化合物、其医药组合物和其用途 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| WO2008130951A1 (en) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
| US8188083B2 (en) * | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온 |
| EP2205565B1 (en) | 2007-09-14 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| MX2010002536A (es) | 2007-09-14 | 2010-08-10 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas. |
| US8119658B2 (en) * | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| EP2220083B1 (en) | 2007-11-14 | 2017-07-19 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2072516A1 (en) * | 2007-12-21 | 2009-06-24 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists |
| US8263630B2 (en) | 2008-02-12 | 2012-09-11 | Bristol-Myers Squibb Company | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| WO2009126861A2 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
| US8324241B2 (en) * | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| MX2011002042A (es) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| NZ593951A (en) | 2009-02-06 | 2013-01-25 | Ortho Mcneil Janssen Pharm | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| AU2010212590B2 (en) * | 2009-02-10 | 2013-01-10 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| EP2414344A1 (en) * | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted indolo-pyridinone compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| KR20120024555A (ko) | 2009-05-07 | 2012-03-14 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절제로서의 신규 치환된 인다졸 및 아자-인다졸 유도체 |
| MX2011012055A (es) * | 2009-05-11 | 2011-12-06 | Astrazeneca Ab | [1,2,4] triazolo [4,3-b] piridazinas como ligandos del receptor de androgeno. |
| EA020672B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалс, Инк. | Производные 1,2,4-триазоло[4,3-a]пиридина и их применение для лечения или предупреждения неврологических и психиатрических расстройств |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US8946266B2 (en) | 2009-07-15 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| KR20120089643A (ko) | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
| JP5775871B2 (ja) * | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| EP2523949B1 (en) | 2010-01-15 | 2014-08-20 | Janssen Pharmaceuticals Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| EA026385B9 (ru) | 2010-07-02 | 2017-08-31 | Джилид Сайэнс, Инк. | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| EP2671582B1 (en) | 2011-02-01 | 2016-07-13 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
| JP2014508794A (ja) | 2011-03-24 | 2014-04-10 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | γ−セクレターゼ調節剤としての新規な置換トリアゾリルピペラジンおよびトリアゾリルピペラジン誘導体 |
| CN105693645B (zh) | 2011-05-10 | 2018-10-09 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
| ES2575092T3 (es) | 2011-06-27 | 2016-06-24 | Janssen Pharmaceutica, N.V. | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina |
| NO3175985T3 (OSRAM) | 2011-07-01 | 2018-04-28 | ||
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| CN103874702B (zh) | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| US9062045B2 (en) | 2011-09-15 | 2015-06-23 | Novartis Ag | Triazolopyridine compounds |
| ES2585009T3 (es) | 2012-05-16 | 2016-10-03 | Janssen Pharmaceuticals, Inc. | Derivados de 3,4-dihidro-2H-pirido[1,2-a]pirazina-1,6-diona sustituidos útiles para el tratamiento de (inter alia) enfermedad de Alzheimer |
| RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
| KR102171706B1 (ko) | 2012-07-09 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 포스포디에스테라아제 10 효소의 억제제 |
| WO2014100158A1 (en) | 2012-12-18 | 2014-06-26 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| JP6275161B2 (ja) | 2012-12-20 | 2018-02-07 | ヤンセン ファーマシューティカ エヌ．ベー． | γセクレターゼ調節剤としての新規な三環式３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体 |
| WO2014111457A1 (en) | 2013-01-17 | 2014-07-24 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| ES2677115T3 (es) | 2013-03-12 | 2018-07-30 | Vertex Pharmaceuticals Incorporated | Derivados de manosa para tratar las infecciones bacterianas |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
| JO3367B1 (ar) * | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| US9738642B2 (en) | 2013-09-19 | 2017-08-22 | Bristol-Myers Squibb Company | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders |
| US9580422B2 (en) | 2013-10-22 | 2017-02-28 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| TW201609722A (zh) * | 2013-12-13 | 2016-03-16 | 美國禮來大藥廠 | 新穎三唑并吡啶化合物 |
| WO2015097121A1 (en) | 2013-12-23 | 2015-07-02 | Norgine B.V. | Compounds useful as ccr9 modulators |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| UA121965C2 (uk) | 2014-01-21 | 2020-08-25 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
| KR102502485B1 (ko) | 2014-01-21 | 2023-02-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| CA2939793A1 (en) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| US9580420B2 (en) * | 2014-08-06 | 2017-02-28 | Bristol-Meyers Squibb Company | Process for the preparation of 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol and novel intermediates therefor |
| US10292970B2 (en) | 2014-12-02 | 2019-05-21 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use |
| SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| CN110402244B (zh) | 2015-08-12 | 2023-02-03 | 因赛特公司 | Lsd1抑制剂的盐 |
| SG10202010414QA (en) | 2016-04-22 | 2020-11-27 | Incyte Corp | Formulations of an lsd1 inhibitor |
| WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| JP2024525160A (ja) | 2021-06-18 | 2024-07-10 | アリゴス セラピューティクス インコーポレイテッド | Ｐｄ－ｌ１を標的とするための方法及び組成物 |
| TW202328139A (zh) | 2021-12-16 | 2023-07-16 | 美商艾利格斯醫療公司 | 用於靶向ｐｄ－ｌ１之方法及組成物 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3597423A (en) | 1966-08-31 | 1971-08-03 | Boehringer Mannheim Gmbh | 5-nitrofuryl-2-s-triazolo-(4,3-a)-pyridine derivatives |
| US4358453A (en) | 1982-01-08 | 1982-11-09 | Schering Corporation | 1,2,4-Triazolo[4,3-a]pyridines |
| DE3540149A1 (de) * | 1985-11-13 | 1987-05-14 | Boehringer Mannheim Gmbh | Verwendung von 1-(benztriazol-4-yloxy)3-(2-(2-methoxyphenoxy) -ethylamino)-2-propanol als antiglaukommittel, optisch aktive r und s isomere dieser substanz, verfahren zur herstellung derselben sowie arzneimittel, die diese substanzen enthalten |
| NZ224714A (en) * | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| CA2026792A1 (en) | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
| IL96432A0 (en) | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
| JP3531169B2 (ja) | 1996-06-11 | 2004-05-24 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| IL127911A0 (en) | 1996-07-25 | 1999-11-30 | Merck Sharp & Dohme | Substituted triazolo-pyridazine derivatives as ligands for gaba receptors |
| GB2345443A (en) | 1999-01-08 | 2000-07-12 | Merck Sharp & Dohme | Use of triazolo-pyridazines for treating premenstrual syndrome |
| MXPA01010916A (es) | 1999-04-28 | 2002-06-21 | Reddy Research Foundation | Heterociclos biciclicos sustituidos, procedimiento para su preparacion y su uso como agentes contra la obesidad y como agentes hipocolesterolemicos. |
| JP2000319277A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| CN1496366A (zh) | 2001-03-09 | 2004-05-12 | �Ʒ� | 作为抗炎剂的三唑并吡啶 |
| JP4250756B2 (ja) | 2001-07-06 | 2009-04-08 | 株式会社大万 | 遊技機 |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| JP4368683B2 (ja) | 2002-02-01 | 2009-11-18 | メルク エンド カムパニー インコーポレーテッド | 糖尿病、肥満症および脂質代謝異常の治療に有用な１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤 |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| US7005523B2 (en) * | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| BR0313961A (pt) | 2002-08-30 | 2005-07-19 | Pfizer Prod Inc | Processos e intermediários para preparar triazolo-piridinas |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| ES2264795T3 (es) | 2003-02-14 | 2007-01-16 | Pfizer Products Inc. | Triazolo-piridinas como compuestos antiinflamatorios. |
| JP2006522747A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 縮合１，２，４−トリアゾールの薬学的使用 |
| US20060247245A1 (en) | 2003-05-05 | 2006-11-02 | Yuelian Xu | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands |
| US8026264B2 (en) | 2003-05-29 | 2011-09-27 | Merck Sharp And Dohme Corp. | Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1 |
| CA2529558A1 (en) * | 2003-07-01 | 2005-01-13 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| GB0325745D0 (en) | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| GB0326029D0 (en) | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| JP2007519726A (ja) | 2004-01-26 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態 |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| JP2008508337A (ja) | 2004-08-02 | 2008-03-21 | シュバルツ ファルマ アクチェンゲゼルシャフト | インドリジンカルボキサミド並びにそのアザ及びジアザ誘導体 |
| HRP20080608T3 (hr) | 2004-08-12 | 2008-12-31 | Pfizer Inc. | Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze |
| CA2577478A1 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
| JP2008509985A (ja) | 2004-08-18 | 2008-04-03 | ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー | 炎症治療用の新規トリアゾロピリジン化合物 |
| CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| CA2580409C (en) | 2004-09-16 | 2013-08-13 | Astellas Pharma Inc. | Triazole derivative or salt thereof |
| JP2008514622A (ja) | 2004-09-24 | 2008-05-08 | スミスクライン ビーチャム コーポレーション | 化合物 |
| WO2006036932A2 (en) | 2004-09-27 | 2006-04-06 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
| EP1797042B1 (en) | 2004-09-29 | 2009-01-07 | F.Hoffmann-La Roche Ag | Indozolone derivatives as 11b-hsd1 inhibitors |
| WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
| EP1810677A1 (en) | 2004-10-08 | 2007-07-25 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
| ES2300054T3 (es) | 2004-10-13 | 2008-06-01 | Merck Patent Gmbh | Derivados de la n,n'- difenilurea adecuados como inhibidores de cinasas. |
| AU2005297531B2 (en) | 2004-10-13 | 2011-06-23 | Merck Patent Gmbh | Phenylurea derivatives used as inhibitors of tyrosinkinase for treating tumors |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| ATE430746T1 (de) | 2004-10-19 | 2009-05-15 | Smithkline Beecham Cork Ltd | Crf-rezeptor-antagonisten und zugehörige verfahren |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| CA2588350A1 (en) | 2004-10-25 | 2006-05-04 | University Of Medicine And Dentistry Of New Jersey | Anti-mitotic anti-proliferative compounds |
| DK1807072T3 (da) | 2004-10-29 | 2009-03-16 | Lilly Co Eli | Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1 |
| EP1666467A1 (en) | 2004-11-08 | 2006-06-07 | Evotec AG | 11Beta-HSD1 Inhibitors |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| AU2005311451A1 (en) | 2004-12-01 | 2006-06-08 | Merck Serono Sa | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
| WO2006080533A1 (ja) | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | ３－アミノ－１,２,４－トリアゾール誘導体 |
| JPWO2007007688A1 (ja) | 2005-07-08 | 2009-01-29 | 持田製薬株式会社 | ３，５−ジアミノ−１，２，４−トリアゾール誘導体 |
-
2006
- 2006-06-07 US US11/448,946 patent/US7572807B2/en active Active
- 2006-06-08 AU AU2006258077A patent/AU2006258077B2/en not_active Ceased
- 2006-06-08 EP EP06772525A patent/EP1912986B1/en active Active
- 2006-06-08 MX MX2007015283A patent/MX2007015283A/es active IP Right Grant
- 2006-06-08 WO PCT/US2006/022260 patent/WO2006135667A1/en not_active Ceased
- 2006-06-08 KR KR1020087000470A patent/KR20080018942A/ko not_active Ceased
- 2006-06-08 AR ARP060102405A patent/AR057357A1/es unknown
- 2006-06-08 JP JP2008515911A patent/JP5124450B2/ja not_active Expired - Fee Related
- 2006-06-08 PE PE2006000635A patent/PE20070002A1/es not_active Application Discontinuation
- 2006-06-08 ES ES06772525T patent/ES2392656T3/es active Active
- 2006-06-08 TW TW095120382A patent/TW200716116A/zh unknown
-
2007
- 2007-11-26 NO NO20076054A patent/NO20076054L/no not_active Application Discontinuation
-
2009
- 2009-07-27 US US12/509,541 patent/US8158648B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006258077B2 (en) | 2012-02-23 |
| MX2007015283A (es) | 2008-02-25 |
| EP1912986B1 (en) | 2012-09-05 |
| US8158648B2 (en) | 2012-04-17 |
| JP2008543764A (ja) | 2008-12-04 |
| EP1912986A1 (en) | 2008-04-23 |
| AU2006258077A1 (en) | 2006-12-21 |
| TW200716116A (en) | 2007-05-01 |
| ES2392656T3 (es) | 2012-12-12 |
| JP5124450B2 (ja) | 2013-01-23 |
| US20090306084A1 (en) | 2009-12-10 |
| US7572807B2 (en) | 2009-08-11 |
| US20060281750A1 (en) | 2006-12-14 |
| KR20080018942A (ko) | 2008-02-28 |
| NO20076054L (no) | 2008-03-04 |
| WO2006135667A1 (en) | 2006-12-21 |
| PE20070002A1 (es) | 2007-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057357A1 (es) | Heterociclos nitrogenados como inhibidores de heteroaril 11-beta hidroxiesteroide deshidrogenasa tipo 1. composiciones farmaceuticas | |
| AR054385A1 (es) | Inhibidores de la triazolopiridin -11- beta - hidroxiesteroide- deshidroogenasa tipo 1 | |
| AR068601A1 (es) | Triazolopiridinas como inhibidores de 11- beta hidroxiesteroide tipo i | |
| AR067562A1 (es) | Compuestos heterociclicos inhibidores de kinasa | |
| AR053235A1 (es) | Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias | |
| AR069596A1 (es) | Regulador del crecimiento de plantas | |
| AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
| AR078320A1 (es) | Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres. | |
| CO4700468A1 (es) | Inhibidores de transferasa de proteina farnesilada | |
| AR072373A1 (es) | Tiadiazoliloxifenilamidinas, el uso de las mismas como fungicidas en composiciones y metodos de uso, proceso para su preparacion e intermediarios de sus sintesis. | |
| AR049483A1 (es) | Combinacion de herbicidas | |
| ECSP045218A (es) | "novedosos inhibidores de la gamma secretasa" | |
| AR035610A1 (es) | Pirimidin sulfamidas, intermediarios, composiciones farmaceuticas, un procedimiento para su manufactura, el uso de dichos compuestos para la produccion de composiciones farmaceuticas | |
| AR070998A1 (es) | Derivados de naftiridina, un procedimiento para su preparacion y la de sus intermediarios de sintesis, una composicion herbicida que los comprende y un metodo para controlar malezas selectivamente que los emplea. | |
| AR045414A1 (es) | Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen. | |
| AR078461A1 (es) | Inhibidores macrociclicos de la replicacion de virus de la hepatitis c | |
| AR079749A2 (es) | Derivados de azaindoles heterociclicos inhibidores de quinasas jak-3, aurora a y rock, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades del sistema nervioso central y trastornos inmunologicos y/o alergicos. | |
| CO5640090A2 (es) | Inhibidores del factor inhibidor de la migracion de los macrofagos y etodo para su identificacion | |
| AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| AR060268A1 (es) | Tiazolil - dihidro - indazoles | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR041883A1 (es) | Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| CO5261507A1 (es) | Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos | |
| AR037237A1 (es) | Compuesto de pirazolo de anillo fusionado, composicion que lo comprende y su uso para fabricar dicha composicion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |